New drug combination for elderly patients with aggressive lymphoma

Plain-English translation of NCT07397832 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new combination treatment called the CRP regimen—made up of three medications: , , and —for elderly patients with a type of aggressive lymphoma called double-positive DLBCL. The goal is to see if this combination is safe, well-tolerated, and effective at treating this cancer in older adults who have never received treatment before. Researchers hope this medication combination might be a better option than standard treatments currently available.

Double-positive DLBCL is a particularly aggressive form of lymphoma that can be hard to treat. This medication is being tested because it may work better against this specific type of cancer while being easier for elderly patients to tolerate than traditional chemotherapy.

Do you qualify?

You likely qualify if…

you are at least 70 years old, or between 60–69 years old with certain functional limitations
you have been diagnosed with untreated double-positive diffuse large B-cell lymphoma (DLBCL) confirmed by biopsy
you have at least one measurable tumor visible on a PET-CT scan
your blood counts and organ function (kidney, liver) are adequate or any abnormalities are due to the lymphoma itself
you have a life expectancy of at least 6 months

You likely don't qualify if…

you have had any prior cancer treatment, including chemotherapy, immunotherapy, or radiation therapy for lymphoma
you have a history of severe allergic reactions to antibody-based medications or monoclonal antibodies
you have heart disease, a recent heart attack, or unstable chest pain in the past 12 months
you have an active, untreated infection or uncontrolled bleeding
you are pregnant or breastfeeding

What participation looks like

If you join this trial, you will receive the three-drug combination medication over multiple treatment cycles, with a maximum of six cycles. You will visit the clinic regularly for infusions and blood tests to check how well the treatment is working and to monitor for any side effects. The trial takes place at multiple hospitals, and your doctors will closely watch your health throughout the study to ensure the treatment is safe and effective for you.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(1 site)

China

Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin Municipality